Morgan Stanley
ONCT

Morgan Stanley’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Morgan Stanley’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,152
Closed -$18.7K – 8244
2024
Q3 		$18.7K Sell
14,152
-915
-6% -$4.42K ﹤0.01% 6525
2024
Q2 		$115K Buy
15,067
+4,267
+40% +$36.8K ﹤0.01% 5919
2024
Q1 		$97.2K Buy
10,800
+1,502
+16% +$13.2K ﹤0.01% 6004
2023
Q4 		$99.7K Buy
9,298
+4,399
+90% +$31.7K ﹤0.01% 6163
2023
Q3 		$29.4K Hold
4,899
– – ﹤0.01% 6358
2023
Q2 		$33.8K Buy
4,899
+1,580
+48% +$10.4K ﹤0.01% 6364
2023
Q1 		$52.1K Sell
3,319
-282
-8% -$5.55K ﹤0.01% 6277
2022
Q4 		$72K Buy
3,601
+117
+3% +$2.33K ﹤0.01% 6126
2022
Q3 		$62K Sell
3,484
-18,749
-84% -$402K ﹤0.01% 6311
2022
Q2 		$493K Sell
22,233
-2,995
-12% -$66.8K ﹤0.01% 5434
2022
Q1 		$702K Sell
25,228
-6,138
-20% -$223K ﹤0.01% 5202
2021
Q4 		$1.42M Buy
31,366
+4,973
+19% +$335K ﹤0.01% 4832
2021
Q3 		$2.2M Buy
26,393
+12,669
+92% +$1.05M ﹤0.01% 4487
2021
Q2 		$1.3M Buy
13,724
+11,384
+486% +$1.35M ﹤0.01% 4931
2021
Q1 		$390K Sell
2,340
-82
-3% -$10.8K ﹤0.01% 5296
2020
Q4 		$237K Buy
2,422
+1,080
+80% +$68.3K ﹤0.01% 5508
2020
Q3 		$46K Buy
1,342
+275
+26% +$13.5K ﹤0.01% 5751
2020
Q2 		$61K Buy
1,067
+525
+97% +$29.6K ﹤0.01% 5613
2020
Q1 		$32K Sell
542
-48
-8% -$3.58K ﹤0.01% 5645
2019
Q4 		$47K Buy
590
+139
+31% +$14.4K ﹤0.01% 5878
2019
Q3 		$45K Buy
451
+80
+22% +$8.19K ﹤0.01% 5766
2019
Q2 		$49K Buy
371
+341
+1,137% +$52.7K ﹤0.01% 5615
2019
Q1 		$5K Sell
30
-304
-91% -$45.3K ﹤0.01% 6335
2018
Q4 		$36K Sell
334
-303
-48% -$60.6K ﹤0.01% 5850
2018
Q3 		$140K Buy
637
+565
+785% +$1.36M ﹤0.01% 5587
2018
Q2 		$154K Sell
72
-52
-42% -$132K ﹤0.01% 5624
2018
Q1 		$309K Buy
124
+123
+12,300% +$274K ﹤0.01% 5270
2017
Q4 		$1K Hold
1
– – ﹤0.01% 6520
2017
Q3 		$1K Sell
1
-1
-50% -$900 ﹤0.01% 6479
2017
Q2 		$1K Buy
2
+1
+100% +$613 ﹤0.01% 6536
2017
Q1 		$0 Sell
1
-2
-67% -$1.47K ﹤0.01% 6632
2016
Q4 		$1K Buy
3
+1
+50% +$1.07K ﹤0.01% 6473
2016
Q3 		$3K Sell
2
-1
-33% -$872 ﹤0.01% 6333
2016
Q2 		$2K Sell
3
-1
-25% -$935 ﹤0.01% 6375
2016
Q1 		$3K Sell
4
-15
-79% -$13K ﹤0.01% 6366
2015
Q4 		$19K Sell
19
-32
-63% -$42.3K ﹤0.01% 6055
2015
Q3 		$54K Sell
51
-5
-9% -$7.31K ﹤0.01% 5697
2015
Q2 		$116K Buy
56
+33
+143% +$46.9K ﹤0.01% 5508
2015
Q1 		$22K Sell
23
-39
-63% -$38.8K ﹤0.01% 6020
2014
Q4 		$64K Buy
62
+56
+933% +$50K ﹤0.01% 5731
2014
Q3 		$7K Sell
6
-33
-85% -$48.7K ﹤0.01% 6274
2014
Q2 		$74K Buy
39
+18
+86% +$35.6K ﹤0.01% 5622
2014
Q1 		$44K Buy
21
+5
+31% +$12.5K ﹤0.01% 5758
2013
Q4 		$37K Sell
16
-47
-75% -$108K ﹤0.01% 5705
2013
Q3 		$178K Buy
63
+3
+5% +$14.9K ﹤0.01% 4932
2013
Q2 		$552K Buy
+60
New +$462K ﹤0.01% 4192

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Morgan Stanley's ONCT Position: Q4 2024 in Review

Morgan Stanley sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 14,152 shares — an estimated $18.7K sold.

Morgan Stanley first reported a position in ONCT in Q2 2013 and held it in 46 quarters. The position peaked at $2.2M in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Morgan Stanley reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Morgan Stanley sold 14,152 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $18.7K.
  • Morgan Stanley first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 46 quarters.
  • Morgan Stanley's Oncternal Therapeutics, Inc. Common Stock position peaked at $2.2M in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.